Title:
USE OF MITOXANTRONE LIPOSOME IN COMBINATION WITH CAPECITABINE IN TREATING NASOPHARYNGEAL CARCINOMA
Document Type and Number:
WIPO Patent Application WO/2024/046246
Kind Code:
A1
Abstract:
Use of a mitoxantrone liposome and capecitabine in treating nasopharyngeal carcinoma, in particular recurrent and/or metastatic nasopharyngeal carcinoma. The present invention further provides a method for treating nasopharyngeal carcinoma, in particular recurrent and/or metastatic nasopharyngeal carcinoma, the method comprising administering a therapeutically effective dose of the mitoxantrone liposome and capecitabine to a patient with nasopharyngeal carcinoma. The combination of the mitoxantrone liposome and capecitabine exhibits superior efficacy in patients with nasopharyngeal carcinoma, thereby providing a new treatment option for patients with nasopharyngeal carcinoma.
Inventors:
LI CHUNLEI (CN)
LIU YANPING (CN)
LI MENGMENG (CN)
HUANG WEI (CN)
DU YANLING (CN)
HE LIJUAN (CN)
WANG SHIXIA (CN)
DONG QI (CN)
WANG DONG (CN)
XUE JIANFEI (CN)
LIU YANPING (CN)
LI MENGMENG (CN)
HUANG WEI (CN)
DU YANLING (CN)
HE LIJUAN (CN)
WANG SHIXIA (CN)
DONG QI (CN)
WANG DONG (CN)
XUE JIANFEI (CN)
Application Number:
PCT/CN2023/115149
Publication Date:
March 07, 2024
Filing Date:
August 28, 2023
Export Citation:
Assignee:
CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN)
International Classes:
A61K31/7068; A61K31/136; A61P35/00; A61P35/04
Domestic Patent References:
| WO2022127760A1 | 2022-06-23 | |||
| WO2004056379A1 | 2004-07-08 |
Other References:
XIAOJIU: "[Nasopharyngeal Cancer] Recruitment of patients with nasopharyngeal cancer treated with the marketed drug Duenda Injection combined with capecitabine", YUGE MEDICAL, 7 July 2023 (2023-07-07), XP093145686
Attorney, Agent or Firm:
CHINA PATENT AGENT (H.K.) LTD. (CN)
Download PDF: